Kardigan, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing precision medicines for cardiovascular diseases with high unmet medical needs. The company's business model centers on in-licensing and advancing late-stage therapeutic candidates that target the underlying pathophysiology of heart conditions, moving beyond traditional symptom management. Kardigan's pipeline includes three primary clinical-stage programs: danicamtiv, an oral cardiac myosin activator for genetic dilated cardiomyopathy (DCM); ataciguat, a soluble guanylate cyclase activator for moderate calcific aortic valve stenosis (CAVS); and tonlamarsen, an antisense oligonucleotide for acute severe hypertension (ASH). A key differentiator for Kardigan is its proprietary "Cardiac Intelligence" platform, which incorporates Prolaio's cardiovascular data collection and analytics technology. This platform utilizes artificial intelligence, FDA-cleared algorithms, and high-density patient data from wearable devices to enhance clinical study design, improve patient responder matching, and track efficacy. By integrating deep cardiovascular biology with advanced analytics, Kardigan aims to accelerate drug development and increase the probability of clinical success. The company operates primarily in the United States, with offices in Princeton, New Jersey, and South San Francisco, California. As a pre-revenue clinical-stage biotech, Kardigan relies on venture capital and public market funding to advance its pipeline toward commercialization.
How many years of EBITDA are required to pay off the company's net debt, according to the official accounting standard IFRS16. As a market consensus, a value of up to 3 years of leverage is accepted for most companies.
How much the company's debt represents in % in relation to its equity. As a market consensus, a value less than or equal to 1 is accepted, above that leverage can end up hurting the final result at some point.
The current ratio helps investors understand more about a company's ability to cover its short-term debt with its current assets and make apples-to-apples comparisons with its competitors and peers.
The quick ratio measures a company's capacity to pay its current liabilities without needing to sell its inventory or obtain additional financing and is considered a more conservative measure than the current ratio, which includes all current assets as coverage for current liabilities.
The interest coverage ratio is used to measure how well a firm can pay the interest due on outstanding debt and is is calculated by dividing a company's earnings before interest and taxes (EBIT) by its interest expense during a given period. Generally, a higher coverage ratio is better, although the ideal ratio may vary by industry.
...and much more!